Pimavanserin
- Generic Name
- Pimavanserin
- Brand Names
- Nuplazid
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34FN3O2
- CAS Number
- 706779-91-1
- Unique Ingredient Identifier
- JZ963P0DIK
- Background
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT and HT receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pim...
- Indication
用于伴随帕金森氏病精神病幻觉和妄想的治疗。
- Associated Conditions
- Delusions, Hallucinations
- Associated Therapies
- -
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 358
- Registration Number
- NCT04373317
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, AZ, Tucson, Arizona, United States
🇺🇸South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04292223
- Locations
- 🇺🇸
Global Health Research Center, Inc., Miami Lakes, Florida, United States
🇺🇸Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, United States
🇺🇸The Orthopedic Foundation, New Albany, Ohio, United States
Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT04188392
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04164758
- Locations
- 🇺🇸
Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
🇺🇸Tucson Neuroscience Research, Tucson, Arizona, United States
🇺🇸Galiz Research, Hialeah, Florida, United States
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT04000009
- Locations
- 🇸🇰
Centrum Zdravia R.B.K., s.r.o., Svidnik, Slovakia
🇸🇰Liptovska nemocnice s poliklinikou MUDr. Ivana Stodolu, Psychiatricke oddelenie, Liptovsky Mikulas, Slovakia
🇸🇰EPAMED s r.o., Kosice, Slovakia
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT03968159
- Locations
- 🇺🇸
IPC Research, Waukesha, Wisconsin, United States
🇺🇸Collective Medical Research, LLC, Prairie Village, Kansas, United States
🇺🇸Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 595
- Registration Number
- NCT03623321
- Locations
- 🇨🇿
A-shine s.r.o./ Lekarna Centrum, Plzen, Czechia
🇷🇺Regional Specialized Psychiatric Hospital #2, Tonnel'nyy, Kochubeev District, Russian Federation
🇷🇺Federal Siberian Sci Clinical Center of Med and Bio, Krasnoyarsk, Russian Federation
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 784
- Registration Number
- NCT03575052
- Locations
- 🇵🇱
RCMed Oddzial Sochaczew, ul. _eromskiego 41A, Sochaczew, Poland
🇺🇸Boston Center Memory, Newton, Massachusetts, United States
🇺🇸Reliable Clinical Research, LLC, Hialeah, Florida, United States
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03482882
- Locations
- 🇺🇸
Associated Neurologists, P.C., Danbury, Connecticut, United States
🇺🇸ATP Clinical Research, Inc., Costa Mesa, California, United States
🇺🇸CNS Network, Torrance, California, United States
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 996
- Registration Number
- NCT03121586
- Locations
- 🇺🇸
141-Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸114-Northwestern University, Chicago, Illinois, United States
🇺🇦582-SI Institute of Neurology,Psychiatry&Narcology of NAMSU, Kharkiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.